Stock Screener App

Gratuito -

1.04

0.97% +0.01

Unicycive Therapeutics Inc (UNCY)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie

Q2 2024 EPS Estimates for Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Lowered by Analyst - Defense World

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney ... - GlobeNewswire

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

GlobeNewswire Inc.

Unicycive Therapeutics (NASDAQ:UNCY) Receives Buy Rating from HC Wainwright - Defense World

Noble Capital maintains Outperform on Unicycive shares By Investing.com - Investing.com Canada

Investing.com Canada

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance UK

Yahoo Finance UK

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - Defense World

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

GlobeNewswire Inc.

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference - Yahoo Finance

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

GlobeNewswire Inc.

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress - GlobeNewswire

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Unicycive Announces $50 Million Private Placement

GlobeNewswire Inc.

Unicycive Announces $50 Million Private Placement - GlobeNewswire

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

GlobeNewswire Inc.

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference - Yahoo Finance

UNCY Stock Quote Price and Forecast - CNN

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

GlobeNewswire Inc.

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) - GlobeNewswire

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

GlobeNewswire Inc.

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug ... - Yahoo Finance

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely? - Simply Wall St

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

GlobeNewswire Inc.

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate - Yahoo Finance

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

GlobeNewswire Inc.

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

Zacks Investment Research

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update - Yahoo Finance

Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

GlobeNewswire Inc.

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

GlobeNewswire Inc.

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

GlobeNewswire Inc.

Why Is Unicycive Therapeutics (UNCY) Down 24% Today? - InvestorPlace

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Therapeutics provides preclinical pharmacokinetic profile of UNI-494 - BioWorld Online

BioWorld Online

Unicycive Announces Full Year 2022 Financial Results and Provides Business Update - Yahoo Finance

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb - GlobeNewswire

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results - PR Newswire

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results - PR Newswire

Unicycive Therapeutics Announces Pricing of Initial Public Offering - PR Newswire

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis - MarketBeat

UNCY IPO News - Kidney disease biotech Unicycive Therapeutics sets terms for $25 million IPO - Renaissance Capital

Renaissance Capital

Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the ... - PR Newswire

$77.56

0.77%

$149.40

1.20%

$29.98

1.11%

$172.85

1.06%

$365.81

2.87%

$90.61

2.55%

Apri su Yahoo | Apri su Google | Aperto in Finviz